The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

Detalhes bibliográficos
Autor(a) principal: Mari, Jair de Jesus [UNIFESP]
Data de Publicação: 2004
Outros Autores: Lima, Mauricio Silva de [UNIFESP], Costa, Anna Maria Niccolai [UNIFESP], Alexandrino, Neusa, Rodrigues-Filho, Salomao, Oliveira, Irismar Reis de, Tollefson, Gary D.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1007/s00406-004-0514-1
http://repositorio.unifesp.br/handle/11600/43579
Resumo: Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
id UFSP_53a79843ab963a290bb17f65a9901ffd
oai_identifier_str oai:repositorio.unifesp.br/:11600/43579
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disordersschizophreniaTardive dyskinesiarandomized controlled trialolanzapinetypical antipsychoticAims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.Univ Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, BrazilFed Univ Pelotas, Dept Psychiat, Eli Lilly, BrazilCatholic Univ Pelotas, Eli Lilly, BrazilHosp Anna Rech, Rio Grande Do Sul, BrazilPax Clin Psiquiatrica Goiania, Goias, BrazilUniv Fed Bahia, Dept Neuropsychiat & Neurol, BR-41170290 Salvador, BA, BrazilUniv Fed Sao Paulo, Dept Psiquiatria, BR-04023900 Sao Paulo, BrazilWeb of ScienceDr Dietrich Steinkopff VerlagUniversidade Federal de São Paulo (UNIFESP)Fed Univ PelotasCatholic Univ PelotasHosp Anna RechPax Clin Psiquiatrica GoianiaUniversidade Federal da Bahia (UFBA)Mari, Jair de Jesus [UNIFESP]Lima, Mauricio Silva de [UNIFESP]Costa, Anna Maria Niccolai [UNIFESP]Alexandrino, NeusaRodrigues-Filho, SalomaoOliveira, Irismar Reis deTollefson, Gary D.2018-06-15T17:17:33Z2018-06-15T17:17:33Z2004-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion356-361http://dx.doi.org/10.1007/s00406-004-0514-1European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.10.1007/s00406-004-0514-10940-1334http://repositorio.unifesp.br/handle/11600/43579WOS:000226092900002engEuropean Archives Of Psychiatry And Clinical Neuroscienceinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-05-02T13:59:21Zoai:repositorio.unifesp.br/:11600/43579Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-05-02T13:59:21Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
title The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
spellingShingle The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
Mari, Jair de Jesus [UNIFESP]
schizophrenia
Tardive dyskinesia
randomized controlled trial
olanzapine
typical antipsychotic
title_short The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
title_full The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
title_fullStr The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
title_full_unstemmed The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
title_sort The prevalence of Tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders
author Mari, Jair de Jesus [UNIFESP]
author_facet Mari, Jair de Jesus [UNIFESP]
Lima, Mauricio Silva de [UNIFESP]
Costa, Anna Maria Niccolai [UNIFESP]
Alexandrino, Neusa
Rodrigues-Filho, Salomao
Oliveira, Irismar Reis de
Tollefson, Gary D.
author_role author
author2 Lima, Mauricio Silva de [UNIFESP]
Costa, Anna Maria Niccolai [UNIFESP]
Alexandrino, Neusa
Rodrigues-Filho, Salomao
Oliveira, Irismar Reis de
Tollefson, Gary D.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Fed Univ Pelotas
Catholic Univ Pelotas
Hosp Anna Rech
Pax Clin Psiquiatrica Goiania
Universidade Federal da Bahia (UFBA)
dc.contributor.author.fl_str_mv Mari, Jair de Jesus [UNIFESP]
Lima, Mauricio Silva de [UNIFESP]
Costa, Anna Maria Niccolai [UNIFESP]
Alexandrino, Neusa
Rodrigues-Filho, Salomao
Oliveira, Irismar Reis de
Tollefson, Gary D.
dc.subject.por.fl_str_mv schizophrenia
Tardive dyskinesia
randomized controlled trial
olanzapine
typical antipsychotic
topic schizophrenia
Tardive dyskinesia
randomized controlled trial
olanzapine
typical antipsychotic
description Aims of the study To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). Method The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score > 24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. Result The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2 % for olanzapine and 84.9 % for the conventional treatment (p = 0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C.I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, on the basis of the AIMS scale. Both results favored olanzapine at the end of the follow-up (Morgenstern & Glazer: 25.6 % versus 56.3 %; Schooler & Kane: 16.3 % versus 45.2 %). At the end of the follow-up, by using the overall rating of the AIMS scale, the presence of TD was 2.3 % for olanzapine (2/87), and 16.7 % (12/72) for the conventional treatment. Conclusions The results of this open label naturalistic trial showed that olanzapine had an impact on negative symptoms, decreased general psychopathology and reduced the risk of tardive dyskinesia.
publishDate 2004
dc.date.none.fl_str_mv 2004-12-01
2018-06-15T17:17:33Z
2018-06-15T17:17:33Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1007/s00406-004-0514-1
European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.
10.1007/s00406-004-0514-1
0940-1334
http://repositorio.unifesp.br/handle/11600/43579
WOS:000226092900002
url http://dx.doi.org/10.1007/s00406-004-0514-1
http://repositorio.unifesp.br/handle/11600/43579
identifier_str_mv European Archives Of Psychiatry And Clinical Neuroscience. Darmstadt: Dr Dietrich Steinkopff Verlag, v. 254, n. 6, p. 356-361, 2004.
10.1007/s00406-004-0514-1
0940-1334
WOS:000226092900002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv European Archives Of Psychiatry And Clinical Neuroscience
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 356-361
dc.publisher.none.fl_str_mv Dr Dietrich Steinkopff Verlag
publisher.none.fl_str_mv Dr Dietrich Steinkopff Verlag
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268279932321792